The trademark application KYMPRAME was filed by Immunocore Limited, a corporation established under the laws of the United Kingdom of Great Britain and Northern Ireland (the "Applicant"). The application was published for oppositions on July 13, 2022, and it was registered by office on October 20, 2022 without any oppositions.
The application was filed in English (French was selected as the second language).
Change of name and address of the trademark registration was recorded on November 16, 2022.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of tumorous diseases
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of cancer
Pharmaceutical preparations, biological preparations and bispecific reagents for the treatment of melanoma, lung cancer, ovarian cancer, uterine cancer, breast cancer, neurothelial cancer, endometrial cancer, oesophageal cancer, sarcoma, haematological cancers, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, and head and neck cancers.